ZBIO - Company ID 0001953926
The table below shows Zenas BioPharma, Inc.'s income statement line items across its last 3 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | $10.00M | $5.00M | $50.00M |
| Cost of revenue | - | - | - |
| Gross profit | - | - | - |
| R&D | $168.06M | $139.14M | $60.03M |
| SG&A | $53.32M | $29.75M | $17.11M |
| Operating income | -$383.06M | -$163.89M | -$37.15M |
| Income tax | -$79.00K | $429.00K | $301.00K |
| Net income |
Zenas BioPharma, Inc. reported annual revenue of $10.00M for fiscal year 2025. That is up 100.0% from $5.00M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$377.74M |
| -$156.99M |
| -$37.12M |
| EPS (diluted) | -$8.44 | -$11.89 | -$24.25 |